| Record ID | ia:pharmacotherapyo0000unse_w3f7 |
| Source | Internet Archive |
| Download MARC XML | https://archive.org/download/pharmacotherapyo0000unse_w3f7/pharmacotherapyo0000unse_w3f7_marc.xml |
| Download MARC binary | https://www.archive.org/download/pharmacotherapyo0000unse_w3f7/pharmacotherapyo0000unse_w3f7_meta.mrc |
LEADER: 03912cam 22008174a 4500
001 ocm53932728
003 OCoLC
005 20200602015932.0
008 031210s2004 flua b 001 0 eng
010 $a 2003070272
040 $aDNLM/DLC$beng$cDLC$dYDX$dNLM$dMUQ$dBAKER$dNLGGC$dBTCTA$dYDXCP$dOCLCG$dDEBBG$dOCL$dILU$dBDX$dOCLCF$dIG#$dCRCPR$dOCLCQ$dOCLCO$dOCLCQ$dUKMGB
015 $aGBA4Z4354$2bnb
016 7 $a101200488$2DNLM
016 7 $a010980352$2Uk
020 $a0415303214$q(alk. paper)
020 $a9780415303217$q(alk. paper)
035 $a(OCoLC)53932728
042 $apcc
050 00 $aRC628$b.P47 2004
060 00 $a2004 I-106
060 10 $aWD 210$bP5366 2004
082 00 $a616.3/98061$222
084 $a44.87$2bcl
084 $aOEK 220f$2stub
084 $aOEK 240f$2stub
245 00 $aPharmacotherapy of obesity :$boptions and alternatives /$cKarl G. Hofbauer, Ulrich Keller, Olivier Boss.
260 $aBoca Raton, Fla. :$bCRC Press,$c©2004.
300 $a488 pages :$billustrations ;$c26 cm
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
338 $avolume$bnc$2rdacarrier
504 $aIncludes bibliographical references and index.
505 00 $g1.$tEnergy homeostasis /$rEric Ravussin and Leslie P. Kozak --$g2.$tThe pathophysiology of appetite control /$rJason C.G. Halford and John E. Blundell --$g3.$tGenetics of obesity /$rPhilippe Boutin and Philippe Froguel --$g4.$tAntipsychotic drugs, weight gain, and diabetes /$rTrino Baptista --$g5.$tObesity and associated complications /$rMichael Hamilton and Frank Greenway --$g6.$tPsychosocial aspects of obesity /$rEsther Biedert and Jurgen Margraf --$g7.$tBasic considerations and guidelines for treatment /$rMichael E.J. Lean --$g8.$tWeight loss and cardiovascular risk factors /$rTobias Pischon, James D. Douketis and Arya M. Sharma --$g9.$tWeight loss and associated diseases /$rPaolo M. Suter.
520 1 $a"Pharmacotherapy of Obesity: Options and Alternatives explores current and future options for drug treatment for obesity in the context of pathophysiology and clinical requirements and then puts them into perspective against available alternative treatments."--Jacket.
650 0 $aObesity$xChemotherapy.
650 0 $aWeight loss preparations.
650 12 $aObesity$xdrug therapy.
650 22 $aAnti-Obesity Agents$xtherapeutic use.
650 22 $aDiet, Reducing.
650 22 $aHealth Behavior.
650 6 $aObésité$xChimiothérapie.
650 6 $aProduits amaigrissants.
650 7 $aObesity$xChemotherapy.$2fast$0(OCoLC)fst01042741
650 7 $aWeight loss preparations.$2fast$0(OCoLC)fst01173471
650 17 $aVetzucht.$2gtt
650 17 $aFarmacotherapie.$2gtt
650 17 $aVermageren.$2gtt
650 07 $aFettsucht.$2swd
650 07 $aPharmakotherapie.$2swd
655 7 $aAufsatzsammlung.$2swd
700 1 $aHofbauer, Karl G.
700 1 $aKeller, U.$q(Ulrich)
700 1 $aBoss, Olivier.
856 41 $3Table of contents$uhttp://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&doc_number=012816829&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA
856 42 $3Publisher description$uhttp://catdir.loc.gov/catdir/enhancements/fy0646/2003070272-d.html
938 $aBaker & Taylor$bBKTY$c179.95$d.00$i0415303214$n0004394133$sactive
938 $aBrodart$bBROD$n02084244$c$185.95
938 $aBaker and Taylor$bBTCP$n2003070272
938 $aCRC Press$bCRCP$nIHC00TF1630000
938 $aIngram$bINGR$n9780415303217
938 $aYBP Library Services$bYANK$n100347942
029 1 $aAU@$b000025184349
029 1 $aAU@$b000027572343
029 1 $aAU@$b000027574046
029 1 $aDEBBG$bBV019352810
029 1 $aNLGGC$b266459781
029 1 $aNLM$b101200488
029 1 $aNZ1$b8150854
029 1 $aUKMGB$b010980352
994 $aZ0$bP4A
948 $hNO HOLDINGS IN P4A - 131 OTHER HOLDINGS